Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Publication year range
1.
Rev Bras Ter Intensiva ; 32(2): 245-250, 2020 Jun.
Article in English, Portuguese | MEDLINE | ID: mdl-32667437

ABSTRACT

OBJECTIVE: To assess the relationship between time to focus clearance and hospital mortality in patients with sepsis and septic shock. METHODS: This was an observational, single-center study with a retrospective analysis of the time to clearance of abdominal septic focus. Patients were classified according to the time to focus clearance into an early (≤ 12 hours) or delayed (> 12 hours) group. RESULTS: A total of 135 patients were evaluated. There was no association between time to focus clearance and hospital mortality (≤ 12 hours versus > 12 hours): 52.3% versus 52.9%, with p = 0.137. CONCLUSION: There was no difference in hospital mortality among patients with sepsis or septic shock who had an infectious focus evacuated before or after 12 hours after the diagnosis of sepsis.


Subject(s)
Hospital Mortality , Intraabdominal Infections/mortality , Sepsis/mortality , Shock, Septic/mortality , Aged , Female , Humans , Intraabdominal Infections/therapy , Male , Middle Aged , Retrospective Studies , Sepsis/therapy , Shock, Septic/therapy , Time Factors
2.
Cir Cir ; 88(4): 481-484, 2020.
Article in English | MEDLINE | ID: mdl-32567597

ABSTRACT

BACKGROUND: A level < 35 g/L of albumin (hypoalbuminemia) has been determined as a parameter to predict mortality and morbidity. METHOD: Prospective observational study, in a period of 12 months, to patients diagnosed with sepsis of abdominal origin, they are divided into two groups based on albumin levels (cut: 3.5 g/dL) to assess mortality between both groups. RESULTS: We studied 23 patients admitted to the intensive care unit. The mean albumin was 2.77 g/dL (± 0.71). When calculating the odds ratio (OR) that was a 23-fold greater risk of dying when hypoalbuminemia presented compared to the normal albumin group (OR = 23.3; 95% CI: 1,948 to 279.42). The mean albumin for patients who died was 2.04 g/dL (± 0.31) vs. 3.03 g/dL (± 0.35) (p = 0.02; 95% CI: -1.551 to -0.416). We do not assess morbidity, however, we identify a certain tendency to a longer stay in the ICU which is accompanied by a higher risk of complications and in the end a higher risk of mortality. CONCLUSION: We conclude that hypoalbuminemia represents a predictor of mortality in patients with abdominal sepsis.


ANTECEDENTES: Un valor de albúmina < 35 g/l (hipoalbuminemia) ha demostrado ser un parámetro para predecir mortalidad y morbilidad. MÉTODO: Estudio observacional, prospectivo, en un periodo de 12 meses, en pacientes con diagnóstico de sepsis de origen abdominal a quienes se dividió en dos grupos según las cifras de albúmina (corte: 3.5 g/dl) para valorar la mortalidad en ambos grupos. RESULTADOS: Estudiamos 23 pacientes ingresados a la unidad de terapia intensiva. La media de albúmina fue de 2.77 g/dl (± 0.71). Al calcular la odds ratio (OR) identificamos un riesgo 23 veces mayor de fallecer al presentar hipoalbuminemia en comparación con el grupo con albúmina normal (OR = 23.3; intervalo de confianza del 95% [IC 95%]: 1.948 a 279.42). La media de los valores de albúmina para los pacientes que fallecieron fue de 2.04 g/dl (± 0.31) vs. a 3.03 g/dl (± 0.35) para el otro grupo (IC 95%: −1.551 a −0.416; p = 0.02)]. Aunque no valoramos la morbilidad, identificamos cierta tendencia a un mayor tiempo de estancia en la unidad de terapia intensiva, lo que se acompaña de mayor riesgo de complicaciones y de un mayor riesgo de muerte. CONCLUSIÓN: La hipoalbuminemia representa un predictor de mortalidad en los pacientes con sepsis abdominal.


Subject(s)
Hypoalbuminemia/mortality , Intraabdominal Infections/mortality , Sepsis/mortality , APACHE , Confidence Intervals , Female , Humans , Intensive Care Units , Intraabdominal Infections/blood , Length of Stay , Male , Middle Aged , Odds Ratio , Organ Dysfunction Scores , Prospective Studies , Sepsis/blood , Serum Albumin/analysis
3.
Rev. bras. ter. intensiva ; 32(2): 245-250, Apr.-June 2020. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1138483

ABSTRACT

RESUMO Objetivo: Aferir a relação entre tempo para evacuação de foco e mortalidade hospitalar em portadores de sepse e choque séptico. Métodos: Estudo observacional, unicêntrico, com análise retrospectiva do tempo para evacuação de foco séptico abdominal. Os pacientes foram classificados conforme o tempo para evacuação do foco em grupo precoce (≤ 12 horas) ou tardio (> 12 horas). Resultados: Foram avaliados 135 pacientes. Não houve associação entre tempo para evacuação do foco e mortalidade hospitalar (≤ 12 horas versus > 12 horas): 52,3% versus 52,9%, com p = 0,137. Conclusão: Não houve diferença na mortalidade hospitalar entre pacientes com sepse ou choque séptico que tiveram foco infeccioso evacuado antes ou após 12 horas do diagnóstico de sepse.


ABSTRACT Objective: To assess the relationship between time to focus clearance and hospital mortality in patients with sepsis and septic shock. Methods: This was an observational, single-center study with a retrospective analysis of the time to clearance of abdominal septic focus. Patients were classified according to the time to focus clearance into an early (≤ 12 hours) or delayed (> 12 hours) group. Results: A total of 135 patients were evaluated. There was no association between time to focus clearance and hospital mortality (≤ 12 hours versus > 12 hours): 52.3% versus 52.9%, with p = 0.137. Conclusion: There was no difference in hospital mortality among patients with sepsis or septic shock who had an infectious focus evacuated before or after 12 hours after the diagnosis of sepsis.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Shock, Septic/mortality , Hospital Mortality , Sepsis/mortality , Intraabdominal Infections/mortality , Shock, Septic/therapy , Time Factors , Retrospective Studies , Sepsis/therapy , Intraabdominal Infections/therapy
4.
Hosp Pract (1995) ; 47(4): 171-176, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31585520

ABSTRACT

A high prevalence of invasive candidiasis has been reported in recent years. Patients admitted to an intensive care unit are at the highest risk for invasive candidiasis, mostly due to the severity of their disease, immune-suppressive states, prolonged length of stay, broad-spectrum antibiotics, septic shock, and Candida colonization. Intraabdominal candidiasis comprises a range of clinical manifestations, from just the suspicion based on clinical scenario to fever, leukocytosis, increase in biomarkers to the isolation of the responsible microorganism. In critically ill patients with IAC prompt treatment and adequate source control remains the ultimate goal.


Subject(s)
Antifungal Agents/therapeutic use , Candidiasis, Invasive/drug therapy , Candidiasis, Invasive/physiopathology , Intensive Care Units , Intraabdominal Infections/drug therapy , Intraabdominal Infections/physiopathology , Antifungal Agents/administration & dosage , Biomarkers , Candidiasis, Invasive/mortality , Candidiasis, Invasive/prevention & control , Critical Illness , Humans , Intraabdominal Infections/mortality , Intraabdominal Infections/prevention & control , Mannans/immunology , Procalcitonin/metabolism , Risk Factors , Severity of Illness Index , beta-Glucans/metabolism
5.
Antimicrob Agents Chemother ; 60(4): 2443-9, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26856846

ABSTRACT

Nephrotoxicity is the main adverse effect of colistin and polymyxin B (PMB). It is not clear whether these two antibiotics are associated with different nephrotoxicity rates. We compared the incidences of renal failure (RF) in patients treated with colistimethate sodium (CMS) or PMB for ≥48 h. A multicenter prospective cohort study was performed that included patients aged ≥18 years. The primary outcome was renal failure (RF) according to Risk, Injury, Failure, Loss, and End-stage renal disease (RIFLE) criteria. Multivariate analysis with a Cox regression model was performed. A total of 491 patients were included: 81 in the CMS group and 410 in the PMB group. The mean daily doses in milligrams per kilogram of body weight were 4.2 ± 1.3 and 2.4 ± 0.73 of colistin base activity and PMB, respectively. The overall incidence of RF was 16.9% (83 patients): 38.3% and 12.7% in the CMS and PMB groups, respectively (P< 0.001). In multivariate analysis, CMS therapy was an independent risk factor for RF (hazard ratio, 3.35; 95% confidence interval, 2.05 to 5.48;P< 0.001) along with intensive care unit admission, higher weight, older age, and bloodstream and intraabdominal infections. CMS was also independently associated with a higher risk of RF in various subgroup analyses. The incidence of RF was higher in the CMS group regardless of the patient baseline creatinine clearance. The development of RF during therapy was not associated with 30-day mortality in multivariate analysis. CMS was associated with significantly higher rates of RF than those of PMB. Further studies are required to confirm our findings in other patient populations.


Subject(s)
Acute Kidney Injury/chemically induced , Anti-Bacterial Agents/adverse effects , Colistin/analogs & derivatives , Kidney Failure, Chronic/chemically induced , Polymyxin B/adverse effects , Acute Kidney Injury/drug therapy , Acute Kidney Injury/mortality , Acute Kidney Injury/pathology , Adult , Age Factors , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Body Weight , Colistin/administration & dosage , Colistin/adverse effects , Drug Administration Schedule , Female , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/growth & development , Gram-Negative Bacteria/pathogenicity , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacterial Infections/mortality , Gram-Negative Bacterial Infections/pathology , Humans , Intensive Care Units , Intraabdominal Infections/drug therapy , Intraabdominal Infections/microbiology , Intraabdominal Infections/mortality , Intraabdominal Infections/pathology , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/pathology , Male , Middle Aged , Multivariate Analysis , Polymyxin B/administration & dosage , Prospective Studies , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/microbiology , Respiratory Tract Infections/mortality , Respiratory Tract Infections/pathology , Risk Factors , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL